Normal
Mesoblast doing very well in the last week. On 20 September the company announced continued strong survival outcomes through Day 180 in children with steroid refractory acute Graft Versus Host Disease (aGVHD) treated with Mesoblast's Phase 3 product candidate remestemcel-L.MSB reached 12 month highs today ($2.07) and closed at $2.05, up 9.6% and near its high for the day. It's looking like it may have some more short term momentum.[ATTACH=full]89476[/ATTACH]
Mesoblast doing very well in the last week. On 20 September the company announced continued strong survival outcomes through Day 180 in children with steroid refractory acute Graft Versus Host Disease (aGVHD) treated with Mesoblast's Phase 3 product candidate remestemcel-L.
MSB reached 12 month highs today ($2.07) and closed at $2.05, up 9.6% and near its high for the day. It's looking like it may have some more short term momentum.
[ATTACH=full]89476[/ATTACH]
Hello and welcome to Aussie Stock Forums!
To gain full access you must register. Registration is free and takes only a few seconds to complete.
Already a member? Log in here.
